NEW YORK – Generic versions of the Allergan's top-selling Alzheimer's drug, the subject of a court battle over the company's sales tactics, are now on the market. Allergan wanted to take its original ...
Attorneys are appealing a decision by a Massachusetts federal judge to dismiss a False Claims Act lawsuit because of deceptive practices by them. Judge F. Dennis Saylor IV dismissed the case on April ...
NEW YORK (Reuters) - Purchasers of Allergan Plc's Namenda asked a federal judge on Tuesday to approve a $750 million settlement of claims that the drugmaker conspired to keep generic versions of the ...
Actavis ($ACT) hit a hurdle for Alzheimer's blockbuster Namenda when a court nixed its plot to force patients over to a new, long-acting formula. But as the Dublin ...
Forest Laboratories ($FRX) wants more people to use its once-daily version of Namenda. It is, after all, the formula launched just last year, the one that ...
A federal appeals court confirmed an earlier ruling on Friday that Actavis must keep Alzheimer’s drug Namenda IR, an older formulation of Namenda XR, on the market. New York State Attorney General ...
The Tuesday Science section of the New York Times is always interesting to read, particularly when it contains articles about breaking new science. Unfortunately, advertisements in this section don’t ...
Attempts by Actavis to switch patients to Namenda XR—a newer formulation of its Alzheimer’s disease drug Namenda IR—will come “at a substantial cost to consumers and taxpayers,” the government said.
Memantine HCl 7mg, 14mg, 21mg, 28mg; ext-rel caps. Tabs—60; Titration Pak (28 x 5mg + 21 x 10mg)—1; Oral soln—contact supplier; XR caps 7mg, 21mg—30; 14mg, 28mg—30, 90; XR Titration Pak (7 x 7mg + 7 x ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results